Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832425 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
A Phase 2 study, sponsored by Praxis Precision Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT04832425 is a Phase 2 study that has completed, run by Praxis Precision Medicines. The registered enrollment target is 216 participants.
The verdict
NCT04832425, a Phase 2 study, has completed, sponsored by Praxis Precision Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Interventions
- DRUG Placebo
- DRUG PRAX-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04832425
The ClinicalTrials.gov registry entry for NCT04832425 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04832425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04832425 about?
NCT04832425 is a clinical study titled "A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder". This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
What is the current status of trial NCT04832425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-03-30. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04832425?
The interventions under investigation include: Placebo (DRUG), PRAX-114 (DRUG).
Who is sponsoring clinical trial NCT04832425?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.